Relay Therapeutics (RLAY) Total Current Liabilities (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Total Current Liabilities data on file, last reported at $29.8 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 19.7% year-over-year to $29.8 million in Q1 2026; TTM through Mar 2026 was $29.8 million, a 19.7% decrease from a year earlier, with the FY2025 full-year figure at $25.6 million, down 49.58% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $29.8 million, up from $25.6 million in the prior quarter.
• Over the last five years, Total Current Liabilities for RLAY reached as high as $71.6 million in Q2 2023 and fell as low as $25.6 million in Q4 2025.
• Historically, Total Current Liabilities has averaged $46.0 million across 5 years, with a median of $43.9 million in 2022.
• Across the five-year window, Total Current Liabilities surged 161.95% in 2022 and sank 52.49% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $63.7 million in 2022, then sank by 52.49% to $30.3 million in 2023, then jumped by 67.59% to $50.7 million in 2024, then slumped by 49.58% to $25.6 million in 2025, then increased by 16.31% to $29.8 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $29.8 million in Q1 2026, $25.6 million in Q4 2025, and $32.6 million in Q3 2025.